Basic Information
Voriconazole Accord
Regulatory Information
EMEA/H/C/002669
May 16, 2013
19
May 12, 2025
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows: - treatment of invasive aspergillosis; - treatment of candidaemia in non-neutropenic patients; - treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); - Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Voriconazole Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Voriconazole Accord. For practical information about using Voriconazole Accord, patients should read the package leaflet or contact their doctor or pharmacist.